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The past 30 years have been an important period in
Parkinson’s disease (PD) research. PD is the second most
common neurodegenerative disorder, after Alzheimer’s dis-
ease, and affects 2-3% of the population X65 years of age.
Unfortunately, many studies have shown that individuals
with PD have a higher risk of mortality than the general
population, and sudden unexpected death in Parkinson’s
disease (SUDPAR), an unusual but fatal event, also occurs.
SUDPAR is a poorly described phenomenon, and translational
studies should be considered and evaluated to establish new
frontiers in the field of SUDPAR research.
Since the ‘‘Decade of the Brain’’ was declared, several neu-
ropsychiatric diseases, including PD, are now seen as speci-
fic diseases with explicable causes and effective measures
of prevention, treatment and rehabilitation (1-4).
PD is one the most common neurodegenerative diseases
and is characterized by tremors, muscular rigidity, slowed
movements and postural imbalance resulting from progres-
sive neuronal loss in the substantia nigra; this neuronal loss
causes striatal dopamine deficits and intracellular inclusions
containing aggregates of a-synuclein (5-9). Despite rapid
advances in our understanding of PD at various levels (from
cellular mechanisms to more sophisticated forms of treat-
ment) (10), neuroscientists cannot comprehensively assess
the risk of PD-related death. Unfortunately, PD patients have
a higher risk of mortality than the general population (11-18).
In fact, a recent 38-year follow-up study demonstrated that
the mortality of PD patients does not increase during the first
decade after disease onset but increases thereafter, eventually
reaching twice the level of that of the general population
(5,19). The main causes of death for these patients were pneu-
monia and cerebrovascular and cardiovascular diseases (19).
Although increasing insight into the course and patho-
mechanisms of PD has been achieved, including risk factors
that increase mortality rates, much of the disease remains a
mystery (5,10-12,19,20). Importantly, previous studies sug-
gest that PD is not a benign condition and is occasionally
associated with sudden unexpected death in PD (SUDPAR)
(21,22).
The causes of SUDPAR are unknown, but cardiovascular
risk factors (B60% of people with PD have cardiovascular
abnormalities) may play an important role (22-25). Notably,
one practical problem in studying the risk factors, mechan-
isms and prevention of SUDPAR is that the condition is
relatively uncommon. Therefore, the development of transla-
tional studies in PD patients who carry a high risk of pre-
mature mortality would be of interest to researchers (21,22).
Matsumoto et al. reviewed clinical data and the causes of
death of 16 PD patients who underwent postmortem exami-
nations (23). Their study revealed that four of 16 PD patients
died of SUDPAR without any satisfactory causes detected by
autopsy, making SUDPAR the second most common cause of
death among the population evaluated (23). Based on these
results, the authors proposed that, although bias is derived
from postmortem examinations, a non-negligible number of
PD patients die of SUDPAR (23).
A substantial increase has occurred in the number of
scientific publications on PD during the last three decades
(5,10). However, how many of these publications were
studies on mortality in PD? Our research group perfor-
med a descriptive review of the published literature on
mortality in PD research since the ‘‘Decade of the Brain’’ was
declared. We found 143,006 articles associated exclusively
with PD and 1,982 scientific papers related to mortality in PD
(Figure 1).
Approximately 2% of the research articles published in
the scientific community since the ‘‘Decade of the Brain’’
was declared are related to mortality or to aspects associated
with SUDPAR. These studies indicate that life expectancy
is reduced in patients with PD compared to the general
population, irrespective of comorbidities, suggesting that
specific characteristics of PD are responsible for the increasedDOI: 10.6061/clinics/2017(11)01
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mortality (13,14,26). Over the past 30 years, several long-
term clinical follow-up studies have identified that age at
onset, motor severity, dementia and psychotic symptoms
are independent risk factors of mortality in PD patients (26).
However, information on SUDPAR remains insufficient.
What is SUDPAR? The first step in the process of character-
izing any community-wide disease condition is the definition
of the problem (27). SUDPAR is a category of death in indi-
viduals with PD and not a condition of the disorder. As has
been widely discussed in epilepsy (28), SUDPAR is particu-
larly difficult to investigate in translational studies due to
its rarity and the insufficiency of postmortem examinations
(21-23,28-30). SUDPAR could be defined simply as the unex-
pected death of a patient with PD without any satisfactory
causes of death determined by autopsy. After this definition
was proposed, several studies evaluated the effects of poten-
tial risk factors that could increase the probability of mor-
tality in PD patients, such as age at onset, duration of PD,
gender, motor severity and drug treatment (polypharmacy)
(5,20-22,25,26,31). These risk factors may be directly rela-
ted to the occurrence of SUDPAR, but further research is
required to establish their precise roles as potential SUDPAR
risk factors. Moreover, the mechanisms of SUDPAR remain
unknown. Human and experimental research suggest that
cardiac abnormalities and autonomic dysfunction play key
roles in SUDPAR (21-23,31-33). While doubts still exist and
some speculative proposals have been described (21-22,33),
the best approach is to try to prevent possible cardiac abnor-
malities in PD patients. Accordingly, appropriate global car-
diovascular assessments of individuals with PD should be
performed. First, a comprehensive clinical history including the
evaluation of a possible family history of SUDPAR should be
obtained. Second, a full physical examination is fundamental.
Third, individuals with PD should reduce cardiovascular risk
factors, such as cigarette smoking, obesity, high blood pressure,
hyperglycemia, hyperlipidemia, and alcohol intake, with the
aim of minimizing heart disease and fatal cardiovascular
events. Fourth, neurologists and cardiologists should develop
a close clinical convergence. Whenever necessary, strategies for
routine cardiovascular screening (e.g., ECG, Holter-monitoring
and echocardiography) should be undertaken to further
reduce the likelihood of SUDPAR. Finally, to better understand
the incidence, potential risk factors, principal mechanisms
and preventive strategies of SUDPAR, well-designed clinical
studies and basic research in validated animal models should
be conducted.
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